An important message from NCRVA regarding coronavirus (COVID-19).

COVID-19 & Your Appointment
Northern California Retina Vitreous Associates logo for print
  • Daly City: 650-994-2100
  • San Mateo: 650-340-0111
  • Mountain View: 650-963-3460
  • Monterey: 831-373-6280
  • East San Jose: 408-251-3500
  • West San Jose: 408-356-8818
Reset Text size:
Reset Text size:

Clinical Trials

Retinal Vein Occlusion

Active Studies

BEACON (Kodiak)

A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with Visual Impairment Due to Treatment-naïve Macular Edema Secondary to Retinal Vein Occlusion (RVO).

COMINO (Roche)

A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB IN PATIENTS WITH MACULAR EDEMA SECONDARY TO CENTRAL RETINAL OR HEMIRETINAL VEIN OCCLUSION.

KSI-CL-101 (Kodiak Sciences)

A Phase 1b Open Label, Multi-center Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects with wet Age-related Macular Degeneration, Diabetic Macular Edema, and Retinal Vein Occlusion.

Completed Studies

BRAVO (Genentech)

Phase 3 study of the efficacy and safety of ranibizumab (Lucentis) compared to sham injection in Branch Retinal Vein Occlusions.

COPERNICUS (Regeneron)

Phase 3 study of the safety, tolerability and biological effect of aflibercept (Eylea) for Central Retinal Vein Occlusions.

CRUISE (Genentech)

Phase 3 study of the efficacy and safety of ranibizumab (Lucentis) compared to sham injection in Central Retinal Vein Occlusions.

GENEVA (Allergan)

Phase 3 study of the efficacy of the Dexamethasone Intravitreal Implant (Ozurdex) in Retinal Vein Occlusions.

ICON (ICON Biosciences)

Phase 1 open label dose escalation study of the safety and tolerability of a sustained release Intravitreal Liquid Drug Delivery using Triamcinolone Acetonide.

NEWTON (NCRVA and Regeneron)

A 1 year Prospective study of Aflibercept (Eylea) for previously treated Macular Edema associated with Central Retinal Vein Occlusion.

RAPTOR (Novartis)

An Eighteen-Month, Two-Arm, Randomized, Double-Masked, Multi-center, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Macular Edema secondary to Branch Retinal Vein Occlusion (RAPTOR)

RAVEN (Novartis)

An Eighteen-Month, Two-Arm, Randomized, Double-Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Macular Edema secondary to Central Retinal Vein Occlusion (RAVEN)

SAPPHIRE (Clearside Biomedical)

A phase 3, 12 month, randomized, masked controlled trial to study the safety and efficacy of suprachoroidal CLS-TA in conjunction with intravitreal aflibercept in subjects with retinal vein occlusion.

SCORE2 (NEI)

A 1 year study of comparative treatment between bevacizumab (Avastin) and aflibercept (Eylea) for Retinal Vein Occlusion.

SCORE2 Long Term Follow-Up Phase (NEI)

A multicenter, non-interventional extension study to understand the long-term efficacy and safety of anti-VEGF treatments on SCORE2 participants who completed the 12 month parent study.

SHORE (Genentech)

Phase 4 study evaluating different dosing regimens of ranibizumab (Lucentis).

VIBRANT (Regeneron)

A 1 year, Phase 3 study of the efficacy, safety and tolerability of aflibercept (Eylea) compared to Laser for the treatment of Branch Retinal Vein Occlusion.